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Accepted 29 December 2018Background and Aims: Placement of the duodenal-jejunal bypass liner (DJBL) leads to rapid weight loss and res-
toration of insulin sensitivity in a similar fashion to bariatric surgery. Increased systemic bile acid levels are can-
didate effectors for these effects through postprandial activation of their receptors TGR5 and FXR. We aimed to
quantify postprandial bile acid, GLP-1 and FGF19 responses and assess their temporal relation to the weight
loss and metabolic and hormonal changes seen after DJBL placement.
Methods: We performed mixed meal testing in 17 obese patients with type 2 diabetes mellitus (DM2) directly
before, one week after and 6 months after DJBL placement.
Results: Both fasting and postprandial bile acid levels were unchanged at 1 week after implantation, and greatly in-
creased 6 months after implantation. The increase consisted of unconjugated bile acid species. 3 hour-postprandial
GLP-1 levels increased after 1 week and were sustained, whereas FGF19 levels and postprandial plasma courses
were unaffected.
Conclusions:DJBL placement leads to profound increases in unconjugated bile acid levels after 6months, similar to the
effects of bariatric surgery. The temporal dissociation between the changes in bile acids, GLP-1 and FGF19 and other gut
hormone responseswarrant caution about the beneficial role of bile acids after DJBL placement. This observational un-
controlled study emphasizes the need for future controlled studies.
© 2019 Elsevier Inc. All rights reserved.Keywords:
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gophetbord.nl,1. Introduction
Bile acids have gained attention as hormone-like factors in me-
tabolism exerting effects via the transmembrane receptor Takeda
G-coupled protein receptor 5 (TGR5) [1–4]. The feedback repression
of hepatic bile acid synthesis is managed through the nuclear
farnesoid X receptor (FXR) and involves ileal Fibroblast Growth Fac-
tor 19 (FGF19) [4,5]. Intestinal L-cell secretion of glucagon-like pep-
tide 1 (GLP-1) is one of the best-described ways of in-vivo
stimulation of TGR5 by bile acids [6].
Bile acids have been implicated in the deranged glucose metabolism
of patients with obesity and type 2 diabetes mellitus (DM2) [7,8]. Obe-
sity is characterized by decreased postprandial bile acid concentrations
[9] and increased bile acid synthesis [10]. DM2 patients have increased
postprandial plasma concentrations of the bile acids cholate (CA),
deoxycholate (DCA) and chenodeoxycholic acid (CDCA) [11].
26 F.S. van Nierop et al. / Metabolism Clinical and Experimental 93 (2019) 25–32Bariatric surgery, and the Roux-en-Y gastric bypass procedure
(RYGB) in particular, increases fasting and postprandial bile acid
levels and results in 45% of patients not needing medication after
5 years [12,13]. The Duodenal-Jejunal Bypass Liner (DJBL, GI Dynam-
ics, Lexington, MA) is a 60 cm long impermeable liner, which is deliv-
ered and retrieved endoscopically. Its placement results in weight
loss and improvement of DM2 with lowering of the use of antidia-
betic medication such as sulfonylurea derivatives, metformin and in-
sulin [14–16].
Given the proposed role of bile acids in DM2 and RYGB, we exam-
ined the effects of DJBL placement on the postprandial bile acid re-
sponse at different time points after the procedure.A
C
E
Fig. 1. Postprandial course of bile acids and AUC before DJBL placem2. Material and Methods
2.1. Subjects
Seventeen subjects with obesity and DM2 were included in the
Maastricht University Medical Center, Maastricht, and the Atrium
Medical Center Parkstad, Heerlen, the Netherlands between Febru-
ary and July 2010 as reported previously [17]. Inclusion criteria
were: age between 18 and 65 years; body mass index (BMI) be-
tween 30 and 50 kg/m2; duration of DM2 b10 years; and HbA1c be-
tween 7.5 and 10.0%. Main exclusion criteria have been depicted
earlier [17].B
D
F
ent and after 1 and 24 weeks of DJBL placement. ** = p b 0.05.
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The DJBL was delivered and retrieved endoscopically where after sub-
jects were studied and followed up upon as described previously [17].
Here, we report on three visits: 1) within onemonth prior to implantation
(baseline), 2) oneweek after implantation (week 1), and 3) 24weeks after
implantation, just prior to removal (week 24). Standardizedmeal tolerance
tests were performed. An intravenous cannula was placed for blood sam-
pling. The first sample was drawn after an overnight fast; subsequently a
standard liquid meal was consumed (Ensure Plus, Abbott Laboratories, IL;
333 mL, 500 kcal, 20.8 g protein, 67.3 g carbohydrates, and 16.4 g fat),
followed by collection of blood samples after 30, 60, 90, 120 and 180 min
(BD Vacutainer EDTA tube/EDTA aprotinin tube, BD diagnostics,
Erembodegem-Aalst, Belgium). Samples were immediately cooled, centri-
fuged, and stored at−80 °C until analysis.
2.3. Laboratory Analysis
Bile acid concentrations were determined using a UPLC-tandemMS
method to quantify CA, CDCA, DCA and ursodeoxycholic acid (UDCA) in
their conjugated and unconjugated forms [18]. FGF19 was measured
using an in-house developed ELISA as published previously [19]. Total
bile acids were calculated by adding up all the individual bile acids
measurements.
2.4. Ethics
The study was approved by the Medical Ethics Committee of both cen-
ters and conducted according to the revised version of the Declaration of
Helsinki. Written informed consent was obtained from every subject prior
to study participation. Clinical Trial Registration Number: NCT00985114.Table 1
Bilogram & FGF19.
Bile acid fraction Baseline
Total bile acids
(μmol/L)
Baseline 1.1 (1.5)
Peak 4.8 (9.0)
AUC 679 (642)
Total CA
(μmol/L)
Baseline 0.1 (0.1)
Peak 0.8 (1.3)
AUC 80 (123)
Total CDCA
(μmol/L)
Baseline 0.4 (0.9)
Peak 2.5 (3.7)
AUC 318 (348)
Total DCA
(μmol/L)
Baseline 0.5 (0.4)
Peak 1.6 (3.0)
AUC 222 (278)
Total UDCA
(μmol/L)
Baseline 0.0 (0.1)
Peak 0.5 (0.6)
AUC 45 (39)
Total taurine-conjugated BA
(μmol/L)
Baseline 0.1 (0.8)
Peak 0.7 (1.2)
AUC 50 (126)
Total glycine-conjugated BA
(μmol/L)
Baseline 0.5 (0.8)
Peak 3.4 (5.4)
AUC 468 (543)
Total unconjugated BA
(μmol/L)
Baseline 0.5 (0.6)
Peak 1.3 (1.6)
AUC 156 (125)
Total 12α-OH BA
(μmol/L)
Baseline 0.6 (0.7)
Peak 2.5 (5.0)
AUC 335 (401)
FGF19
(pg/mL)
Baseline 51.9 (37.5)
Peak 70.7 (199.7)
AUC 6303 (7661)
Bilogram Baseline, peak concentration and AUC of bile acid subtypes and FGF19. Values are pre
AUC is μmol/L×min. Overall difference between the three study days was assessed using the F
signed-rank test.
⁎ Denotes significant difference compared to baseline.
† Denotes significant difference compared to week 1.2.5. Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 22 (IBM,
Armonk, NY, USA). Data were visually and statistically assessed for nor-
mality and logarithmically transformed where appropriate. Area-
under-the-curve (AUC) of postprandial plasma levels was calculated
using the trapezoidalmethod; subsequent correction for baseline values
yielded the incremental-area-under-the-curve (iAUC). Peak time was
defined as the first time point at which maximal concentration was
reached. Comparisons between 3 test conditions were made using
Friedman's test to determine significant differences. Individual compar-
isons between 2 test conditions were made with Wilcoxon matched-
pairs signed rank testing. Correlations were assessed using Pearson's
correlation for normally distributed populations or Spearman's Rho for
other data. A p-value of b0.05 was considered statistically significant
after Bonferroni corrections. Data presented are mean and standard de-
viation (μ ± σ) for normally distributed variables or median and inter-
quartile range (m [IQR]) for other variables. Graphs were made using
GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Lining of the Proximal Small Intestine by DJBL Reduces Body Weight
Theweight loss effects of the DJBL have been published previously [17].
At baseline, subjects (14 males, 3 females) were 51 ± 2 years old and
weighed 116.0 ± 5.8 kg with a BMI of 37.0 ± 1.3 kg/m2. One week after
placement of the DJBL, body weight had decreased by 4.3 ± 0.6 kg, corre-
sponding to an excess weight loss of 10.2 ± 1.7% and a BMI reduction of
1.4 ± 0.2 kg/m2 (p b 0.01). After 24 weeks, at the time of device removal,
mean body weight had further decreased resulting in a total weight loss
of 12.7 ± 1.3 kg, and a BMI reduction of 4.1 ± 0.4 kg/m2 (p b 0.01). AllWeek 1 Week 24 p
1.6 (1.4) 7.8 (3.9)⁎† b0.01
5.9 (8.4) 13.1 (6.5)⁎† b0.01
602 (722) 1661 (966)⁎† b0.01
0.2 (0.3) 1.6 (1.3)⁎† b0.01
0.6 (0.6) 3.0 (2.9)⁎† b0.01
69 (261) 315 (306)⁎† b0.01
0.5 (0.6) 3.3 (2.8)⁎† b0.01
2.4 (2.7) 6.0 (4.3)⁎† b0.01
246 (222) 722 (657)⁎† b0.01
0.6 (0.6) 2.8 (2.3)⁎† b0.01
2.4 (2.9) 4.0 (2.6)⁎† b0.01
246 (327) 519 (326)⁎† b0.01
0.2 (0.2) 0.0 (0.2) 0.13
0.4 (0.2) 0.2 (0.3)⁎ 0.03
53 (33) 14 (41) 0.08
0.1 (0.2) 0.0 (0.1)⁎† 0.01
0.5 (0.8) 0.1 (0.1)⁎† b0.01
54 (56) 6 (24)⁎† b0.01
0.6 (1.0) 1.3 (0.9) 0.39
3.9 (5.0) 4.2 (3.3) 0.79
366 (438) 422 (306) 0.19
0.8 (0.4) 6.2 (3.7)⁎† b0.01
1.5 (0.6) 8.1 (6.2)⁎† b0.01
182 (53) 1118 (789)⁎† b0.01
0.8 (0.7) 4.6 (2.8)⁎† b0.01
3.2 (3.5) 6.4 (4.0)⁎† b0.01
324 (404) 834 (467)⁎† b0.01
61.9 (20.4) 43.7 (24.2) 0.09
111.9 (74) 91.8 (127.0) 0.84
7986 (2712) 6694 (3272) 0.10
sented as median (IQR). The unit of bile acid peak and baseline values is μmol/L, the unit of
riedman test. If significant, p-values were calculated using the related-samples Wilcoxon
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subjects (15/17) reported increased feelings of satiety.
3.2. Lining of the Proximal Small Intestine by DJBL Increases Fasting and
Postprandial Unconjugated Bile Acid Levels
All subjects completed the study. AUC, fasting and peak levels of
total bile acids and all bile acid subsets except UDCA were markedly in-
creased 24 weeks after placement but not after 1 week (see Fig. 1 and
Table 1). In fact, the increase of AUCs relied primarily on the increaseA
B
C
Fig. 2. Composition of the postprandial bile acid pool composition (AUC) for the bile acids CA,
(panel A). Composition of the postprandial bile acid pool composition (AUC) for the taurine-, a
24 weeks of DJBL placement (panel B). ** = p b 0.05. Ratio postprandial CA:DCA AUCs before Din fasting plasma bile acids since incremental AUCs were unaffected
by DJBL placement (data not shown). Peak times (time from start of
the meal to the peak of the plasma bile acids) were unchanged for all
bile acids and bile acid subfractions (data not shown).
3.3. The Increase in Plasma Bile Acids by DJBL is Completely Caused by Un-
conjugated Bile Acids
To gain further insight in the composition of the bile acid pool after
overnight fasting, we analysed the different bile acids species as wellCDCA, DCA and UDCA before DJBL placement and after 1 and 24 weeks of DJBL placement
nd glycine-conjugated and unconjugated bile acids before DJBL placement and after 1 and
JBL placement and after 1 and 24 weeks of DJBL placement (panel C). * = p b 0.05.
A
B
Fig. 3. Postprandial courses of individual glycine-conjugated bile acid species, before and 1 and 24 weeks after DJBL placement (panel A). Postprandial courses of individual unconjugated bile acid species, before and 1 and 24 weeks after DJBL
placement (panel A). ** = p b 0.05.
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Fig. 4.Postprandial curves of glucose (panel A), insulin (panel B), GLP-1 (panel C), CCK (panelD) and FGF19 (panel E) beforeDJBLplacement and after 1 and 24weeks ofDJBL, **= p b 0.05.
T = 180 values are missing for FGF19 at baseline.
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largest contributor to the pool during the entire study, followed by
DCA and CA respectively. Remarkably, the increase in plasma bile
acids was completely caused by unconjugated bile acids (Fig. 2,
panel B), which reached significance after 24 weeks. Expressed as
the fraction of total bile acids, unconjugated bile acid AUC rose
from a median of 22% (IQR 13%) at baseline to 26% (IQR 20%, p b
0.01⁎⁎) at week 1 and 76% (IQR 19%, p b 0.01⁎⁎) at week 24 after
placement. Total glycine conjugates were unaltered after 24 weeks
in contrast to the taurine conjugates that showed a ~90% reduction
(Table 1). This pattern was also observed for the individual conju-
gated forms of CA, CDCA and DCA as shown in Fig. 3, emphasizing
the fact that the increase in unconjugated plasma bile acids after
DJBL was not due to one bile acid species. We found no changes in
the ratio of 12α-hydroxylated/non12α-hydroxylated bile acids
(data not shown).3.4. Postprandial Levels of Glucose, Insulin, GLP-1 Cholecystokinin (CCK)
and FGF19
The effects of DJBL on glucose, insulin, GLP-1 and CCK in the stud-
ied subjects have been published previously [16,17]. In summary,
duodenal lining lowered glucose and CCK within one week and led
to increased postprandial AUC of GLP-1 at week 1 and week 24
after DJBL placement (Fig. 4). Insulin levels were not affected. The
only bile acid species that consistently correlated with the AUC of
GLP-1 on all study days, was fasting DCA: baseline: r = 0.50, p b
0.05⁎; week 1 after placement: r = 0.56, p b 0.05⁎; week 24 after
placement: r = 0.63, p b 0.01⁎⁎. No other correlations were detected
for bile acid species to AUC, fasting or peak levels of either glucose,
CCK or GLP-1 (data not shown).
There were no significant differences in either fasting levels, post-
prandial plasma course, or postprandial levels of FGF19 at baseline,
31F.S. van Nierop et al. / Metabolism Clinical and Experimental 93 (2019) 25–32week 1 or week 24 after DJBL placement (see Table 1). However, at
baseline, there were strong correlations between peak FGF19 and virtu-
ally all bile acids (peak total bile acids r= 0.79, p b 0.001⁎⁎⁎; peak total
CA, r = 0.78, p b 0.001⁎⁎⁎; peak total CDCA, r = 0.79, p b 0.001⁎⁎⁎ and
peak total DCA, r = 0.63, p b 0.007⁎⁎⁎ that were lost after DJBL place-
ment. Likewise, postprandial AUC of FGF19 and AUC of total bile acids
correlated (r = 0.84, p b 0.001⁎⁎⁎) at baseline but not after treatment.
Individual AUCs of CA, CDCA or DCA did not correlate significantly
with FGF19 AUC after Bonferroni correction. FGF19 samples at week 0
for timepoint 180 min were missing due to insufficient sample volume.
4. Discussion
Duodenal lining markedly increases fasting and postprandial levels
of unconjugated bile acids 24 weeks after placement of the DJBL. The
TGR5 target GLP-1 was higher after 1 and 24weeks. Initial strong corre-
lations of bile acids and FGF19 were lost at 1 week after placement. Bile
acid levelswere unchanged 1week after placement, which supports the
notion that the bile acid pool size may have increased gradually over
time although metabolic improvements occurred immediately after
placement [17]. This is in linewith several studies performed in patients
after RYGB surgery [12,20–23].
The DJBL-induced increase of bile acids was dependent on unconju-
gated bile acids, and more exaggerated compared to changes seen after
RYGB surgery [12,21,23–25]. Dietary weight loss only marginally in-
creases specific bile acids [26]. Hepatic conjugation of newly synthesized
bile acids to occurs in the peroxisome, whereas re-conjugation of
deconjugated bile acids occurs in the cytosol [27]. The reconjugation ma-
chinery is able to conjugate a potentially enlarged bile acid pool, as N99%
of serum bile acids in patients treated with large doses of unconjugated
ursodeoxycholate is conjugated [28]. Changes in the gut microbiome are
possibly responsible for our results. Bacterial deconjugation is complete
in the cecum and gut biotransformation of bile acids (i.e. ratios of CA:
DCA and CDCA:LCA) were altered after 24 weeks [29]. The DJBL may
have led to a different interplay between bile acids, gut bacteria and the
gut lumen with effects on entero-endocrine hormones that regulate mo-
tility, transit and bile salt reabsorption via the apical sodium-dependent
bile acid transporter (ASBT). This could result in increased deconjugation
and increased colonic uptake not buffered by liver clearance [30]. The ini-
tial increase in unconjugated bile acids after DJBL placement may go un-
noticed until the amount of unconjugated bile acids reaches a tipping
point, exceeding liver clearance.
It has been suggested that the increase in plasma bile acids after
RYGB surgery may be due to increased bile acid recirculation and FXR
dependent transcriptional upregulation [31,32]. The former could be
achieved by adaptive growth and concomitant increases in ASBT. How-
ever, previous studies after RYGB were not unequivocal [12,21,23–25].
The increased GLP-1 seems attributable to increased TGR5 signalling
in the gut, although insulin secretion remained unchanged. Moreover,
GLP-1 levels increased at week 1 whereas bile acid levels increased
later which may be explained by an early increase of bile acids in the
gut that were not yet noticeable peripherally. Indeed, our findings are
in partial agreement with a previous study that examined the effects
of DJBL and also found increased GLP-1 levels [33]. However, this
study did not investigate subfractions of bile acids. Interestingly, they
were able to observe an increase in FGF19 that did not result in lower
plasma bile acids. Most subjects with obesity or DM2 exhibit reduced
serum FGF19 levels [34]. Here, FGF19 levels were unchanged through-
out the entire study. The mismatch between plasma bile acid and
FGF19 levels is difficult to explain FXR sensitivity to its ligand could be
decreased, either as a cause of the increased circulating bile acid pool
or as a consequence of it. A recent study in healthy subjects revealed
that FXR agonist-induced repression of bile salt synthesis occurred
without alterations in FGF19 level [35].
Our study has a few limitations. First, wewere only able to perform a
short mixed-meal test, which may have missed differences inpostprandial signalling factors that occur later (such as FGF19 that
peaks between 3 and 4 h). Also, we were not able to document the
exactmomentwhere changes in bile acid homeostasis became apparent
due to the timing of experiments at week 1 and 24. Additionally, this
was an observational uncontrolled study emphasizing the need for fu-
ture controlled studies. Finally, we did not quantify satiety and appetite
with visual analogue scores.
In this study, duodenal lining led to beneficial improvements in glu-
cosemetabolism andweight in patients with DM2. Surprisingly, uncon-
jugated bile acids showed a marked increase after 24 weeks whereas
the increase in GLP-1 was evident after one week. In contrast, correla-
tions of bile acids and FGF19were abolished immediately. Our data sug-
gest that future studies should be comparing effects of duodenal lining
and other means of weight loss on bile acids, GLP-1 and FGF19 taking
into account the time course of these changes.
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